Bioray Pharmaceutical Co., Ltd.

This early-phase study tests a new drug called BR115 in 120 people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the right dose. Participants receive the drug weekly after an initial two doses, and the study moni…

This phase 3 trial tests whether a new drug called HS627 (a biosimilar) works as well as pertuzumab when given with trastuzumab and docetaxel before surgery for HER2-positive breast cancer. About 408 people with early-stage or locally advanced breast cancer took part. The main go…

This study tests a new drug, zuberitamab, in 135 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. Participants receive either zuberitamab (two doses two weeks apart) or the standard drug cyclosporine. The main goal is to see if zuberitam…